Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
QLS31905 plus chemotherapy in CLDN18.2+ advanced solid tumors
NCT06041035Phase 2Not yet recruiting
- Sponsor
- Qilu Pharmaceutical
- Start
- Oct 2023
- Primary completion
- Oct 2024
- Modality
- Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label trial of QLS-31905 in solid tumor, pancreatic cancer (PC), gastric cancer (GC) and 2 more (3 cohorts), sponsored by Qilu Pharmaceutical. Primary endpoints: Maximum Tolerated Dose at 12 months, Phase 2 Recommended Dose at 12 months and 1 more. Planned start Oct 2023; status: not yet recruiting.
02
Drugs
QLS-31905
03
Conditions
solid tumorpancreatic cancer (PC)gastric cancer (GC)gastroesophageal junction cancerbiliary tract cancer (BTC)
Beyond the preview
Go deeper on NCT06041035.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06041035.